SciSparc Ltd. Form 6-K Summary
Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed this Form 6-K on May 2, 2023. The filing reports a material corporate event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements.
Material Changes
The primary material event reported is the completion of treatment for the last patient enrolled in the Company's Phase IIa clinical trial for Alzheimer's Disease and agitation. This milestone was announced via a press release dated May 2, 2023.
Guidance, Outlook, and Risks
The filing incorporates the May 2, 2023 press release by reference into the Company's registration statements on Form F-3 and Form S-8. No specific financial guidance, management commentary on future performance, or detailed risk factors are provided within the text of this specific Form 6-K.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the Phase IIa trial design and next steps.
- Review the Company's most recent Form 20-F or quarterly reports for current financial status, cash runway, and debt levels.
- Confirm the status of the clinical trial data readout timeline, as this filing only confirms treatment completion.